A study found no significant HRQOL differences between Erleada-based therapies and ADT plus AAP for advanced castration-sensitive prostate cancer.

In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.

The 80-patient placebo-controlled randomized Phase 2 study will evaluate the efficacy of opaganib in combination with Bayer's darolutamide in men with metastatic castrate-resistant prostate cancer ...

The 80-patient placebo-controlled randomized Phase 2 study will evaluate the efficacy of opaganib in combination with Bayer's darolutamide in men with metastatic castrate-resistant ...

Nubeqa was approved for a similar indication in the US last July, and will compete in the nmCRPC market with Janssen's Erleada (apalutamide) and Astellas/Pfizer's Xtandi (enzalutamide).

The Inflation Reduction Act (IRA), passed in 2022, made changes to the way drugs are covered and reimbursed in Medicare.

Trusted source of information on Prostate Health that includes articles, news, videos, animations, quizzes, calculators and ...

Patients over the age of 50 have an increased risk of mortality following hip fracture, which is dependent on factors such as health and post-fracture comorbidities. Findings from a meta-analysis ...

This study aimed to investigate the nature of life impacts following ankle fractures with the intention of describing a thematic conceptual framework based on these lived experiences of people who ...

Researchers will use a lipidomic biomarker test to select patients with a poor prognosis who may benefit from an investigational combination therapy.